Keywords: s-p, temodal, eu, schering-plough, asked, european, medicines
S-P's Temodal in EU
Article | 31 March 1999
Schering-Plough has asked the European Medicines Evaluation Agency forclearance to market Temodal (temozolomide) for the second-line treatment of anaplastic astrocytoma ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
